USPTO Examiner ARNOLD ERNST V - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19061465FORMULATIONS OF BENDAMUSTINEFebruary 2025May 2025Allow310NoNo
18923418CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEOctober 2024March 2025Allow510YesNo
18739378SOLVENT-BASED METHOD FOR MAKING NANOCOMPOSITE PHARMACEUTICAL MATERIALJune 2024August 2024Allow200NoNo
18646171FORMULATIONS OF BENDAMUSTINEApril 2024August 2024Allow410NoNo
18646329FORMULATIONS OF BENDAMUSTINEApril 2024April 2025Allow1220NoNo
18599125METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020YesNo
18599127METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020NoNo
18598402Devices for Treating Diseases and ConditionsMarch 2024May 2024Allow200YesNo
18444175ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDEFebruary 2024April 2025Abandon1410NoNo
18427459CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEJanuary 2024July 2024Allow610NoNo
18426704TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTSJanuary 2024April 2025Abandon1510NoNo
18408463METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTJanuary 2024January 2025Allow1320NoNo
18405512COMPOSITION USED FOR THERAPEUTIC TREATMENT OF SKIN DISEASEJanuary 2024April 2025Abandon1510NoNo
18542954PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERYDecember 2023February 2025Allow1411NoNo
18519530POLYMER PARTICLES FOR NEUTROPHIL INJURYNovember 2023January 2025Allow1310NoNo
18373603Medical Implants And Methods Of ManufactureSeptember 2023August 2024Allow1100NoNo
18239715Nanoparticles Containing a Taxane and their UseAugust 2023May 2025Allow2010NoNo
18453988PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONSAugust 2023April 2025Allow2011NoNo
18451593MINIMIZING AGGLOMERATION OF DRUG PARTICLE COATING MATERIAL DURING STORAGE TO STABILIZE DISINTEGRATION TIMES OF PHARMACEUTICAL PRODUCTSAugust 2023April 2025Allow2010NoNo
18448809MICROBIOLOGICAL TRANSPORT MEDIUM AND METHODS OF USING THE SAMEAugust 2023March 2025Abandon1911NoNo
18362813METALLO-LIOTHYRONINEJuly 2023February 2025Abandon1910NoNo
18224232BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSIONJuly 2023May 2025Abandon2211NoNo
18221143Powder Blend Processability Improvements Through Minimal Amounts Of Synergistically Selected Surface Coating AgentsJuly 2023April 2024Allow920YesNo
18219623ENCAPSULATED PROBIOTICJuly 2023June 2025Allow2340NoNo
18329399INSOLUBLE TRANSDERMAL MICRONEEDLE PATCH, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFJune 2023September 2023Allow300NoNo
18204728CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEJune 2023October 2023Allow510NoNo
18307184DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOFApril 2023July 2024Allow1510NoNo
18295863METHOD FOR FORMING A SILVER-CONTAINING NANOCOMPOSITE PHARMACEUTICAL COMPOUNDApril 2023May 2024Allow1400NoNo
18127862LIPOSOME ENCAPSULATING CYSTEAMINE AND RESVERATROL IN SEPARATE COMPARTMENTSMarch 2023June 2025Abandon2740NoNo
18127633PHARMACEUTICAL LOTION OR SALVE UTILIZING MIXED METAL HYDROXIDE ANTIMICROBIAL CHARGED PARTICLESMarch 2023August 2023Allow410YesNo
18190839SOLUTION FOR ORAL ADMINISTRATIONMarch 2023October 2024Abandon1810NoNo
18186304METHOD OF TREATING SPINAL DISKMarch 2023July 2024Allow1610NoNo
18115789ANTIBACTERIAL SURFACE OF METAL-ORGANIC FRAMEWORK-CHITOSAN COMPOSITE FILMSMarch 2023February 2025Allow2320YesNo
18092569INTRADIALYTIC USE OF SODIUM NITRITEJanuary 2023February 2024Allow1300YesNo
18086506METHOD OF MANUFACTURING A BIOIMPLANTDecember 2022October 2024Allow2220YesNo
18081238FORMULATIONS OF BENDAMUSTINEDecember 2022October 2023Allow1030YesNo
18081251FORMULATIONS OF BENDAMUSTINEDecember 2022November 2023Allow1130YesNo
18072473CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMENovember 2022July 2023Allow810NoNo
18070134METHOCARBAMOL COMPOSITIONS AND RELATED METHODSNovember 2022July 2024Allow2010NoNo
17991157METHODS OF PRODUCING AN OSTEOINDUCTIVE CALCIUM PHOSPHATE MATERIAL FOR BONE GRAFTINGNovember 2022July 2024Abandon2010NoNo
17987983DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALSNovember 2022October 2024Allow2331YesNo
17987989DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALSNovember 2022May 2024Allow1811YesNo
17978700Method for Coating Pharmaceutical SubstratesNovember 2022December 2023Allow1430YesNo
17972172Pharmaceutical Formulation with Improved Solubility and BioavailabilityOctober 2022May 2025Allow3130NoNo
17966092IMPLANTS INCLUDING MODIFIED DEMINERALIZED CORTICAL BONE FIBERS AND METHODS OF MAKING SAMEOctober 2022December 2024Allow2620NoNo
18045377SYSTEMS AND METHODS TO REPAIR TISSUE DEFECTSOctober 2022January 2025Allow2730YesNo
17962381COMPOSITIONS AND METHODS FOR PROMOTING CELLULAR METABOLIC FITNESSOctober 2022January 2024Abandon1621YesNo
17930716Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye DisordersSeptember 2022December 2023Abandon1620YesYes
17901258Cartilage Regeneration Using Injectable, In Situ Polymerizable Collagen Compositions Containing Chondrocytes or Stem CellsSeptember 2022October 2023Allow1421NoNo
17895347SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONSAugust 2022May 2024Allow2110NoNo
17819940METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17819942METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow3020NoNo
17819941METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow3020NoNo
17819934METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17819938METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17819675CELLULAR BONE GRAFTS, AND METHODS OF MANUFACTURE AND USEAugust 2022November 2024Allow2730NoNo
17879557METHOD OF TREATING DISEASESAugust 2022October 2022Allow210NoNo
17803470Processes for Breaching Blood-Brain BarrierJuly 2022January 2024Abandon1810NoNo
17859820SHAPE CHANGING DRUG DELIVERY DEVICES AND METHODSJuly 2022December 2023Allow1700YesNo
17858404NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAMEJuly 2022February 2025Abandon3121NoNo
17808390PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1June 2022March 2024Abandon2110NoNo
17840002PHARMACEUTICAL COMPOSITIONS COMPRISING ZINCJune 2022April 2024Abandon2210NoNo
17805749SUPPLEMENT COMPOSITIONS FOR NITROUS OXIDE PATIENTSJune 2022January 2024Abandon1910NoNo
17831821BIOMARKERS FOR JOINT AILMENTS AND USES THEREOFJune 2022September 2024Abandon2811NoNo
17780168PEROXYGEN-BASED SKIN DISINFECTANTS EFFECTIVE AGAINST MYCOBACTERIA AND YEASTSMay 2022March 2025Allow3410NoNo
17747403TREATMENT FOR REDUCING ADVERSE EVENTS INCLUDING CHEMOTHERAPY DISCOMFORT AND OTHER CONDITIONSMay 2022May 2025Abandon3610NoNo
17776866COMPOSITION FOR HAIR TREATMENT, CONTAINING OLEFIN-BASED UNSATURATED HYDROCARBON-CONTAINING OILMay 2022June 2025Allow3711YesNo
17743337COMPOSITIONS AND METHODSMay 2022August 2024Abandon2751YesNo
17771648COMBINATION THERAPY OF CYCLOSERINE AND LITHIUM FOR THE TREATMENT OF DEPRESSIONApril 2022January 2025Allow3310NoNo
17725677PHARMACEUTICAL COMPOSITION COMPRISING GHB GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASEApril 2022September 2024Allow2920NoNo
17721725METHOD OF TREATING DISEASESApril 2022September 2023Allow1700YesNo
17754536SILICA WITH ULTRA-FAST DISSOLUTION PROPERTIESApril 2022February 2025Allow3510NoNo
17760885IMMUNE STIMULATING MICELLE COMPOSITIONMarch 2022April 2025Allow3710YesNo
17693191ENHANCED NITRATE, ELEMENTAL METAL, AND AMINO ACID COMPOSITIONS AND METHODS OF USEMarch 2022January 2025Abandon3451NoNo
17677726CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEFebruary 2022September 2022Allow710YesNo
17753132COMPOSITION FOR DELAYING AND DYEING GREY HAIRFebruary 2022September 2024Allow3100NoNo
17672983ALLOGRAFTS CONTAINING VIABLE CELLS AND METHODS THEROFFebruary 2022December 2024Abandon3440NoNo
17670383A METHOD OF ADMINISTERING NITRIC OXIDE GASFebruary 2022June 2025Allow4051YesNo
17665014MEDICINAL NANOCOMPOSITE AND METHOD OF PREPARATION THEREOFFebruary 2022October 2023Allow2111NoNo
17585170TRANSDERMAL DELIVERY FORMULATIONSJanuary 2022February 2024Abandon2441YesNo
17629560HYDROPHILIC INORGANIC POWDER AND COSMETIC PREPARATION CONTAINING THE SAMEJanuary 2022August 2024Allow3100NoNo
17579278METHOCARBAMOL COMPOSITION AND RELATED METHODSJanuary 2022June 2022Allow510YesNo
17575767DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOFJanuary 2022March 2023Allow1420YesNo
17647877COSMETIC COMPOSITIONSJanuary 2022April 2024Allow2710YesNo
17575035SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONSJanuary 2022July 2022Allow600NoNo
17646241Solid Solution Compositions and Use in Severe PainDecember 2021November 2023Allow2210NoNo
17563944Pharmaceutical Composition Mix A to treat health conditions associated with elevated glucose levelsDecember 2021April 2022Allow310YesNo
17561971Pharmaceutical Composition Mix B to treat health conditions associated with elevated glucose levelsDecember 2021April 2022Allow310YesNo
17547572THREADS OF CROSS-LINKED HYALURONIC ACID AND HYDROXYAPATITEDecember 2021September 2024Abandon3421NoNo
17544445DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALSDecember 2021August 2022Allow811NoNo
17540802Solid Solution Compositions Comprising CannabidiolsDecember 2021July 2023Allow1910NoNo
17540282MULTIFUNCTIONAL POLYMER-NANOPARTICLE COMPOSITE FOR FIRST AID AND WOUND CARE APPLICATIONSDecember 2021May 2024Abandon3030NoNo
17537662PHOTOSTABLE ANTIOXIDANT COSMETIC COMPOSITIONNovember 2021August 2024Allow3211YesNo
17595640SODIUM PERCARBONATE DISSOLVING BATH PRODUCT FORMULATIONNovember 2021April 2023Allow1710YesNo
17531213Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release CoatingNovember 2021February 2024Abandon2710NoNo
17529816TISSUE ENGINEERED SYNTHETIC SUPPORT STRUCTURENovember 2021February 2024Allow2710YesNo
17529827PRESERVING FUNCTIONALLY-COATED API PARTICLES PRODUCED BY SOLVENTLESS MIXING PROCESSES IN AQUEOUS SUSPENSIONNovember 2021November 2024Allow3640YesNo
17529177SYNTHETICALLY LETHAL NANOPARTICLES FOR TREATMENT OF CANCERSNovember 2021February 2025Abandon3940NoNo
17455375SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERYNovember 2021December 2023Abandon2510NoNo
17610598CRYOGEL BIOSCAFFOLDNovember 2021April 2025Allow4111NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARNOLD, ERNST V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
56
Examiner Affirmed
47
(83.9%)
Examiner Reversed
9
(16.1%)
Reversal Percentile
26.1%
Lower than average

What This Means

With a 16.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
179
Allowed After Appeal Filing
18
(10.1%)
Not Allowed After Appeal Filing
161
(89.9%)
Filing Benefit Percentile
11.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ARNOLD, ERNST V - Prosecution Strategy Guide

Executive Summary

Examiner ARNOLD, ERNST V works in Art Unit 1613 and has examined 1,283 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner ARNOLD, ERNST V's allowance rate of 52.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ARNOLD, ERNST V receive 2.35 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ARNOLD, ERNST V is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +11.7% benefit to allowance rate for applications examined by ARNOLD, ERNST V. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.4% of cases where such amendments are filed. This entry rate is in the 34% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 25.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 58.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.4% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 64% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.